Mark J. Coster

Mark J. Coster

Auto-generated profile, based on publicly available information

Mark J. Coster

Griffith Institute for Drug Discovery, Griffith University, Brisbane, Qld 4111, Australia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
LDLanfeng Dong
Lanfeng Dong
VJVictoria J.A. Jameson
Victoria J.A. Jameson
DTDavid Tilly
David Tilly
JCJiri Cerny
Jiri Cerny
EMElahe Mahdavian
Elahe Mahdavian
JNJiri Neuzil
Jiri Neuzil
Mitochondrial complex II (CII) has been recently identified as a novel target for anti-cancer drugs. Mitochondrially targeted vitamin E succinate (MitoVES) is modified so that it is preferentially localized to mitochondria, greatly enhancing its pro-apoptotic and anti-cancer activity. Using genetically manipulated cells, MitoVES caused apoptosis and generation of reactive oxygen species (ROS) in CII-proficient malignant cells but not their CII-dysfunctional counterparts. MitoVES inhibited the succinate dehydrogenase (SDH) activity of CII with IC(50) of 80 μM, whereas the electron transfer from CII to CIII was inhibited with IC(50) of 1.5 μM. The agent had no effect either on the enzymatic activity of CI or on electron transfer from CI to CIII. Over 24 h, MitoVES caused stabilization of the oxygen-dependent destruction domain of HIF1α fused to GFP, indicating promotion of the state of pseudohypoxia. Molecular modeling predicted the succinyl group anchored into the proximal CII ubiquinone (UbQ)-binding site and successively reduced interaction energies for serially shorter phytyl chain homologs of MitoVES correlated with their lower effects on apoptosis induction, ROS generation, and SDH activity. Mutation of the UbQ-binding Ser(68) within the proximal site of the CII SDHC subunit (S68A or S68L) suppressed both ROS generation and apoptosis induction by MitoVES. In vivo studies indicated that MitoVES also acts by causing pseudohypoxia in the context of tumor suppression. We propose that mitochondrial targeting of VES with an 11-carbon chain localizes the agent into an ideal position across the interface of the mitochondrial inner membrane and matrix, optimizing its biological effects as an anti-cancer drug.

31 October 2001 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
IPIan Paterson
Ian Paterson
DCDavid Y.-K. Chen
David Y.-K. Chen
MCMark J. Coster
Mark J. Coster
JAJose Luis Aceña
Jose Luis Aceña
JBJordi Bach
Jordi Bach
RNRoger D. Norcross
Roger D. Norcross

1 June 2011 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LDLanfeng Dong
Lanfeng Dong
VJVictoria J.A. Jameson
Victoria J.A. Jameson
DTDavid Tilly
David Tilly
LPLubomir Prochazka
Lubomir Prochazka
JRJakub Rohlena
Jakub Rohlena
JNJiri Neuzil
Jiri Neuzil

7 June 2011 in Organic Letters
Verified
Journal Article
Closed access
JFJoshua Fischer
Joshua Fischer
GSG. Paul Savage
G. Paul Savage
MCMark J. Coster
Mark J. Coster

1 December 2011 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
JRJakub Rohlena
Jakub Rohlena
LDLanfeng Dong
Lanfeng Dong
KKKatarina Kluckova
Katarina Kluckova
RZRenata Zobalova
Renata Zobalova
JGJacob Goodwin
Jacob Goodwin
JNJiri Neuzil
Jiri Neuzil
Aims: A plausible strategy to reduce tumor progress is the inhibition of angiogenesis. Therefore, agents that efficiently suppress angiogenesis can be used for tumor suppression. We tested the antiangiogenic potential of a mitochondrially targeted analog of α-tocopheryl succinate (MitoVES), a compound with high propensity to induce apoptosis. Results: MitoVES was found to efficiently kill proliferating endothelial cells (ECs) but not contact-arrested ECs or ECs deficient in mitochondrial DNA, and suppressed angiogenesis in vitro by inducing accumulation of reactive oxygen species and induction of apoptosis in proliferating/angiogenic ECs. Resistance of arrested ECs was ascribed, at least in part, to the lower mitochondrial inner transmembrane potential compared with the proliferating ECs, thus resulting in the lower level of mitochondrial uptake of MitoVES. Shorter-chain homologs of MitoVES were less efficient in angiogenesis inhibition, thus suggesting a molecular mechanism of its activity. Finally, MitoVES was found to suppress HER2-positive breast carcinomas in a transgenic mouse as well as inhibit tumor angiogenesis. The antiangiogenic efficacy of MitoVES was corroborated by its inhibitory activity on wound healing in vivo. Innovation and Conclusion: We conclude that MitoVES, a mitochondrially targeted analog of α-tocopheryl succinate, is an efficient antiangiogenic agent of potential clinical relevance, exerting considerably higher activity than its untargeted counterpart. MitoVES may be helpful against cancer but may compromise wound healing. Antioxid. Redox Signal. 15, 2923–2935.

24 May 2005 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
IPIan Paterson
Ian Paterson
MCMark J. Coster
Mark J. Coster
DCDavid Y.-K. Chen
David Y.-K. Chen
KGKarl R. Gibson
Karl R. Gibson
DWDebra J. Wallace
Debra J. Wallace
Stereocontrolled syntheses of the C16–C28 CD-spiroacetal subunit of altohyrtin A/spongistatin 1 (1), relying on kinetic and thermodynamic control of the spiroacetal formation, are described. The kinetic control approach resulted in a slight preference (60 : 40) for the desired spiroacetal isomer. The thermodynamic approach allowed ready access to the desired spiroacetal 2 by acid-promoted equilibration, chromatographic separation of the C23 epimers and resubjection of the undesired isomer to the equilibration conditions. This scalable synthetic sequence provided multi-gram quantities of 2, thus enabling the successful completion of the total synthesis of altohyrtin A/spongistatin 1, as reported in Part 4 of this series.